Description: The ‘Companion Diagnostics Market (2nd Edition), 2014 – 2024’ report provides an extensive study of the growing market of companion diagnostics. The report differentiates personalized medicine diagnostics and companion diagnostics; it has separately defined these two closely associated markets. The research covers various aspects, such as advantages of personalized medicine over traditional medicine and the need for companion diagnostics. In addition to evaluating the marketed and pipeline companion diagnostic tests, the report also includes views on the current state of the companion drugs market.

One of the key objectives of this report is to understand the future evolution of the companion diagnostics market. The proprietary ‘Companion Diagnostics Market Forecasting Model’ allows the likely growth of companion diagnostics tests across various parameters to be predicted. The model, built over a ten year horizon, offers valuable insights on the following:

- Global market evolution, both in terms of volume (number of tests) and the associated sales value (USD billion)
- Regional variation, specifically in the US and European (Germany, Italy, France, Spain and the UK) markets
- Likely adoption of marketed / pipeline tests for specific biomarkers (e.g. EGFR, KRAS, ALK, HER2 and BRAF) till 2024
- Likely adoption of various marketed / pipeline tests for specific indications (e.g. metastatic non-small cell lung cancer, metastatic colorectal cancer, breast cancer and melanoma) till 2024

The report discusses, in detail, the key drivers behind the regional and global growth. The regional evaluation extends to other markets such as Japan, China and Australia. This provides a greater clarity in the differing approaches various regions have towards personalized medicine and companion diagnostics.

The research, analysis and insights presented in this report include the sales of all companion diagnostic tests that are essential before prescription of any companion drug. All actual figures have been sourced and analyzed from publicly available information. The figures mentioned in this report are in USD, unless otherwise specified.

Some highlights of the report include:

- The global companion diagnostics market is likely to grow at an annualized rate of 22.9% over the next ten years; by 2024, over 10 million tests are expected to be conducted annually across various indications.
- In 2013, 18.5% of the new molecular entities (NMEs) were approved with a pharmacogenomic biomarker by the FDA.
- The sales of marketed companion drugs generated estimated revenues of more than USD 26 billion in 2013, with six drugs achieving blockbuster status.
- The pipeline for companion diagnostics is rich with most products being developed with the collaborative effort of pharmaceutical and diagnostics companies; we have identified over 75 drugs which are being co-developed with predictive biomarkers.
- Partnership seems to be the most preferred model for development; since January 2011, there have been more than 90 collaborations between pharmaceutical and diagnostic companies.
- Pharmaceutical companies have displayed keen interest in companion diagnostic start-ups such as Epic Sciences and Nodality. Specifically, Epic Sciences has inked deals with at least six pharmaceutical companies (including Genentech, Celgene and Pfizer) for development of companion diagnostics for cancer drugs.

Research Methodology

Most of the data presented in this report has been gathered by secondary research. Interviews have been conducted with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful to draw out our opinion on how the market will shape up across different regions and drug segments. Where possible, the available data has been checked for accuracy from multiple sources of information.
The secondary sources of information include:

- Annual reports
- Investor presentations
- SEC filings
- Industry databases
- News releases from company websites
- Government policy documents
- Other analysts’ opinion reports

While the focus has been on forecasting the market over the coming ten years, the report also provides an independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

The report is broken down as follows:

- Chapter 2 provides an executive summary of the insights captured in our research. The summary offers a high level view on the likely evolution of companion diagnostics market.

- Chapter 3 provides a general introduction on personalized medicine and explains, in detail, companion diagnostics and their development from pharmacogenomics biomarkers.

- Chapter 4 analyzes the global companion drugs market, including the FDA and EMA approved companion drugs. The chapter provides details on leading companion drugs and indications. It also highlights leading pharmaceutical companies active in this market, along with case studies of some well-known companion drugs.

- Chapter 5 analyzes the global companion diagnostics market, identifying the currently marketed diagnostics and those in the pipeline. This chapter includes estimates on how the overall market is going to evolve globally over the next ten years. A bottom-up approach has been used to forecast details on the number of tests and associated sales value for different biomarker and indication combinations.

- Chapter 6 provides a detailed analysis on the regional market for companion diagnostics. The major markets covered include the US and Europe (Germany, France, Italy, Spain and the UK). It also includes details on companion diagnostic testing in Japan, China and Australia. The chapter highlights policies that govern the approval and reimbursement of in vitro diagnostics (in particular companion diagnostics) and investments made in the field of personalized medicine. In addition, the companion diagnostics approved in these countries have been identified, including the historical data on number of tests conducted in some of the regions. For the US and EU5 markets, regional market forecast over the next ten years has been provided, both in terms of volume and value (by type of biomarker and by type of indication).

- Chapter 7 includes profiles of the key companies in the companion diagnostics market. Each company profile includes information such as financial performance, geographical presence, marketed / pipeline products (including companion drugs and diagnostics) and recent developments.

- Chapter 8 analyzes the theranostics market as a whole with detailed discussion on the role of various stakeholders in the market. It also covers the recent partnerships that have taken place in the theranostics market to develop drug-diagnostic combinations.

- Chapter 9 focuses on the key drivers of companion diagnostics, expanding on the advantages they hold for the delivery of healthcare. It includes a discussion on the tools and technologies promoting their use. The chapter also provides a SWOT analysis capturing the key elements likely to influence future growth.

- Chapter 10 is a collection of transcripts of interviews conducted during the course of this study.

- Chapter 11 summarizes the overall report. This chapter provides a recap of the key takeaways and independent opinion based on the research and analysis described in previous chapters.

- Chapters 12 and 13 are appendices. These provide tabulated data for all the figures provided in the report and a list of companies / organizations mentioned in the report.
Contents:
1. PREFACE
   1.1. Scope of the Report
   1.2. Research Methodology
   1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
   3.1. Context and Background
   3.2. Traditional Medicine and Diagnostics: The One for All Concept
   3.3. Milestone in Biotechnology: Decoding of Human Genetic Code in 2003
   3.4. Changing Face of Medicine: Personalized Medicine and Diagnostics
   3.4.1. Personalized Medicine vs. Traditional Medicine
   3.4.2. Personalized Medicine Diagnostics
   3.4.3. Pharmacogenomic Biomarkers
   3.4.4. Development of Biomarkers Into Companion Diagnostics
   3.4.5. The Three Entry Points for a Companion Diagnostic to Associate with a Drug
   3.4.6. Low Translation Rates of Biomarkers to Companion Diagnostics

4. COMPANION DRUGS MARKET, 2013
   4.1. Chapter Overview
   4.2. 18.5% of the New Molecular Entities were Approved with a Pharmacogenomic Biomarker by FDA
   4.3. Companion Drugs in the Market
   4.3.1. Companion Drugs in the Market have Achieved Blockbuster Status as Well
   4.3.2. Oncology was the Leading Indication Targeted by Companion Drugs
   4.3.3. Roche Laboratories had the Most Number of Successful Companion Diagnostics
   4.4. Case Studies
   4.4.1. Trastuzumab (Herceptin): A Successful Example of Personalized Medicine
   4.4.2. Crizotinib (Xalkori): From Conception to Market in Four Years
   4.4.3. Vemurafenib (Zelboraf): Co-development with Companion Diagnostic Accelerating the Time to Market
   4.4.4. Gefitinib (Iressa): Revival with Companion Diagnostic
   4.4.5. Kalydeco (Ivacaftor): Strong Start to a Promising Future

5. GLOBAL MARKET FOR COMPANION DIAGNOSTICS, 2014 - 2024
   5.1. Chapter Overview
   5.2. Companion Diagnostic: Definition
   5.3. Marketed Companion Diagnostics, 2014
   5.3.1. Preference of LDTs Over Kits
   5.4. Companion Diagnostics in Pipeline: Story of New Entrants
   5.4.1. Oncology Dominates the Pipeline as Well
   5.4.2. Collaboration of Drug-Diagnostic Developers is the Most Common Model
   5.4.3. Start-Ups Gaining Attention
   5.4.4. Companion Imaging Diagnostics on rise
   5.5. Forecast Methodology
   5.6. Global Companion Diagnostics Market, 2014 - 2024: Distribution by Type of Test
   5.6.1. Global KRAS Market, 2014 - 2024: Number of Tests and Sales Forecast
   5.6.2. Global EGFR Market, 2014 - 2024: Number of Tests and Sales Forecast
   5.6.3. Global HER2 Market, 2014 - 2024: Number of Tests and Sales Forecast
   5.6.4. Global ALK Market, 2014 - 2024: Number of Tests and Sales Forecast
   5.6.5. Other Companion Diagnostics, 2014 - 2024: Number of Tests and Sales Forecast
   5.7. Global Companion Diagnostics Market, 2014 - 2024: Distribution by Type of Indication
   5.7.2. Global Metastatic Colorectal Cancer Companion Diagnostics Market, 2014 - 2024
   5.7.4. Global Melanoma Companion Diagnostics Market, 2014 - 2024

6. REGIONAL MARKET FOR COMPANION DIAGNOSTICS, 2014 - 2024
   6.1. Chapter Overview
   6.2. United States
   6.2.1. Current FDA Classification of IVD Tests
   6.2.2. Companion Diagnostic Testing
   6.2.3. FDA Promoting the Development of Companion Diagnostics
RESEARCH AND MARKETS

6.2.5. The US KRAS Market, 2014 - 2024: Number of Tests and Sales Forecast
6.2.6. The US EGFR Market, 2014 - 2024: Number of Tests and Sales Forecast
6.2.7. The US HER2 Market, 2014 - 2024: Number of Tests and Sales Forecast
6.2.8. The US ALK Market, 2014 - 2024: Number of Tests and Sales Forecast
6.2.9. Other Companion Diagnostic Tests in the US, 2014 - 2024: Number of Tests and Sales Forecast
6.2.10. The US Companion Diagnostics Market, 2014 - 2024: Distribution by Type of Indication
6.2.10.2. The US Metastatic Colorectal Cancer Companion Diagnostics Market, 2014 - 2024
6.2.10.3 The US Breast Cancer Companion Diagnostics Market, 2014 - 2024
6.2.10.4. The US Melanoma Companion Diagnostics Market, 2014 - 2024

6.3. Europe (Germany, France, The UK, Italy, Spain)
6.3.1. Regulation of IVDs in Europe: Current State
6.3.2. Proposed Change in Classification to Alter the Regulation of Companion Diagnostics
6.3.3. Other Proposed Changes
6.3.4. Germany
6.3.4.1. Companion Diagnostic Testing
6.3.4.2. Investments in Personalized Healthcare
6.3.4.3. Reimbursement System in Germany
6.3.5. France
6.3.5.1. Diagnostic Testing in France
6.3.5.2. Reimbursement System in France
6.3.5.3. Companion Diagnostic Testing
6.3.5.4. Challenges in the French Companion Diagnostics Market
6.3.5.5. Investments for Future Personalized Diagnostics
6.3.6. The UK
6.3.6.1. Diagnostic Testing in the UK
6.3.6.2. State of HER2, KRAS and EGFR Testing
6.3.6.3. Investments for Future Personalized Diagnostics
6.3.7. Italy
6.3.8. Spain
6.3.8.1. Investments in the field of Personalized Healthcare

6.3.9. Overall EU5 Market for Companion Diagnostics, 2014 - 2024
6.3.10. EU5 KRAS Market, 2014 - 2024: Number of Tests and Sales Forecast
6.3.11. EU5 EGFR Market, 2014 - 2024: Number of Tests and Sales Forecast
6.3.12. EU5 HER2 Market, 2014 - 2024: Number of Tests and Sales Forecast
6.3.13. EU5 ALK Market, 2014 - 2024: Number of Tests and Sales Forecast
6.3.14. Other Companion Diagnostics in EU5, 2014 - 2024: Number of Tests and Sales Forecast
6.4. EU5 Companion Diagnostics Market, 2014 - 2024: Distribution by Type of Indication
6.4.1. EU5 Metastatic non-Small Cell Lung Cancer Companion Diagnostics Market, 2014 – 2024
6.4.2. EU5 Metastatic Colorectal Cancer Companion Diagnostics Market, 2014 - 2024
6.4.3. EU5 Breast Cancer Companion Diagnostics Market, 2014 - 2024
6.4.4. EU5 Melanoma Companion Diagnostics Market, 2014 - 2024

6.5. Japan
6.5.1. Companion Diagnostics Testing
6.5.2. Growth Drivers

6.6. Rest of the World
6.6.2. Companion Diagnostic Testing in Australia
6.6.2.1. Regulatory Framework in Australia
6.6.2.2. Reimbursement Schemes
6.6.2.3. Therapies and Companion Diagnostic Tests
6.6.2.4. Investments in the field of Personalized Medicine

7. PROFILES OF LEADING COMPANIES
7.1. Chapter Overview

7.2. Abbott Molecular
7.2.1. Marked Companion Diagnostics
7.2.2. Pipeline Companion Diagnostics
7.2.3. Partnerships
7.2.4. Financial Performance

7.3. Qiagen
7.3.1. Expanding Through Acquisitions
7.3.2. Marked Companion Diagnostics
7.3.3. Pipeline Companion Diagnostics
7.3.4. Partnerships
7.3.5. Financial Performance
7.3.6. Recent Developments

7.4. Dako (a Subsidiary of Agilent Technologies)
7.4.1. Marked Companion Diagnostics
7.4.2. Pipeline Companion Diagnostics
7.4.3. Partnerships
7.4.4. Financial Performance
7.4.5. Recent Developments

7.5. Roche Laboratories
7.5.1. Marked Companion Diagnostics
7.5.1.1. Marked Companion Diagnostics
7.5.2. Pipeline Companion Diagnostics
7.5.3. Partnerships
7.5.4. Financial Performance

7.6. Novartis
7.6.1. Marked Companion Diagnostics
7.6.1.1. Marked Companion Diagnostics
7.6.2. Pipeline Companion Diagnostics
7.6.3. Partnerships
7.6.4. Financial Performance

7.7. bioMérieux
7.7.1. Expanding Through Acquisitions
7.7.2. Marked and Pipeline Products
7.7.3. Partnerships
7.7.4. Financial Performance

8. ANALYSIS OF THERANOSTICS MARKET: Stakeholders and Business Models
8.1. Chapter Overview
8.2. Stakeholders in the Market
8.3. Theranostic Development Agencies
8.3.1. Pharmaceutical Company
8.3.1.1. Traits a Pharmaceutical Company Looks for in a Companion Diagnostics Developer
8.3.1.2. Pharmaceutical Company Business Models
8.3.2. The Companion Diagnostic Developer
8.3.2.1. Companion Diagnostic Company Business Models
8.3.3. Recent Partnerships
8.3.4. Testing Laboratories
8.3.5. Contract Research Organizations (CROs)
8.3.6. Regulatory Authorities
8.3.7. Buyers/Target Audience
8.3.8. Payers
8.3.9. Companies Providing Ancillary Services

9. MARKET GROWTH DRIVERS
9.1. Chapter Overview
9.2. Low Drug Efficacy Rates
9.3. Poor Drug Compliance
9.4. High Cost of Drug Development
9.5. Phase II and III Drug Failures
9.6. Drug Recalls
9.7. Tools and Technologies Enabling the Move to Companion Diagnostics
  9.7.1. Growing Significance of Biomarkers
  9.7.2. Reducing Costs of Genome Sequencing
9.8. SWOT Analysis
  9.8.1. Strengths
  9.8.2. Weaknesses
  9.8.3. Opportunities
  9.8.4. Threats
10. INTERVIEW TRANSCRIPTS
11. CONCLUSION
  11.1. Companion Diagnostics: An Emerging Market
  11.2. Co-Development and Approval of Companion Diagnostic will be the Preferred Route of Development
  11.3. Key Driving Factors
  11.4. Opportunities Outpace the Threats
  11.5. Concluding Remarks
12. APPENDIX 1: TABULATED DATA
13. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

Figure 3.1 Segments of Personalized Medicine Diagnostics
Figure 3.2 Biomarker to Companion Diagnostics
Figure 4.1 NME Approved by the FDA, 2013 - With or Without Biomarker (%)
Figure 4.2 Companion Drugs Market, 2013 - By Leading Drugs (USD Million, %)
Figure 4.3 Companion Drugs Market, 2013 - By Leading Indication (USD Million, %)
Figure 4.4 Companion Drugs Market, 2013- by Leading Companies (USD million, %)
Figure 4.5 HER2 Expression in Breast Cancer Patients (%)
Figure 4.6 Herceptin Sales, 1998 - 2013 (USD Million)
Figure 4.7 EML4-ALK Expression in non-Small Cell Lung Cancer Patients (%)
Figure 4.8 Timeline for Development of Xalkori and Companion Diagnostic, 2005 - Current
Figure 4.9 Xalkori Sales, 2011 - 2013 (USD Million)
Figure 4.10 BRAF V600E Expression in Metastatic Melanoma Patients (%)
Figure 4.11 Timeline for Development of Zelboraf and Companion Diagnostic, 2006 - Current
Figure 4.12 Zelboraf Sales, 2011- 2013 (USD Million)
Figure 4.13 Iressa Sales, 2005 - 2013 (USD Million)
Figure 4.14 G551D Mutation in Cystic Fibrosis Patients (%)
Figure 4.15 Kalydeco Sales, 2012 - 2013 (USD Million)
Figure 5.1 Global Companion Diagnostics Market, Number of Tests: Split by Category, 2014 - 2024 (# '000)
Figure 5.2 Global Companion Diagnostics Market, Sales Forecast: Split by Category, 2014 - 2024 (USD MM)
Figure 5.3 US Companion Diagnostics Market, Number of Tests: Split by Category, 2014 - 2024 (# '000)
Figure 5.4 US Companion Diagnostics Market, Sales Forecast: Split by Category, 2014 - 2024 (USD MM)
Figure 5.5 EU5 Companion Diagnostics Market, Number of Tests: Split by Category, 2014 - 2024 (# '000)
Figure 5.6 EU5 Companion Diagnostics Market, Sales Forecast: Split by Category, 2014 - 2024 (USD MM)
Figure 5.7 Global KRAS Market, Number of Tests: Split by Category, 2014 - 2024 (# '000)
Figure 5.8 Global KRAS Market, Sales Forecast, 2014 - 2024 (USD MM)
Figure 5.9 Global EGFR Market, Number of Tests: Split by Category, 2014 - 2024 (# '000)
Figure 5.10 Global EGFR Market, Sales Forecast: Split by Category, 2014 - 2024 (USD MM)
Figure 5.11 Global HER2 Market, Number of Tests: Split by Category, 2014 - 2024 (# '000)
Figure 5.12 Global HER2 Market, Sales Forecast: Split by Category, 2014 - 2024 (USD MM)
Figure 5.13 Global ALK Market, Number of Tests, 2014 - 2024 (# '000)
Figure 5.14 Global ALK Market, Sales Forecast, 2014 - 2024 (USD MM)
Figure 5.15 Other Companion Diagnostics, Global Number of Tests, 2014 - 2024 (# '000)
Figure 5.16 Other Companion Diagnostics, Global Sales Forecast, 2014 - 2024 (USD MM)
Figure 5.17 Global Metastatic NSCLC Companion Diagnostic Tests, 2014 - 2024 (# '000)
Figure 5.18 Global Metastatic NSCLC Companion Diagnostic Test Sales Forecast, 2014 - 2024 (USD MM)
Figure 5.19 Global Metastatic Colorectal Cancer Companion Diagnostic Tests, 2014 - 2024 (# '000)
Figure 7.4 Qiagen Personalized Healthcare Sales, 2012 (USD million, %)
Figure 7.5 Agilent Technologies Sales, 2013 –Split by Business Segments (USD Million, %)
Figure 7.6 Roche: Phase 1 Pipeline Molecules (With and Without Companion Diagnostic Development)
Figure 7.7 Roche: Phase 2 Pipeline Molecules (With and Without Companion Diagnostic Development)
Figure 7.8 Roche: Phase 3 Pipeline Molecules (With and Without Companion Diagnostic Development)
Figure 7.9 Roche Group Sales, 2013-Split by Business Segments (USD Million, %)
Figure 7.10 Roche Diagnostics Sales, 2013–Split by Segments (USD Million, %)
Figure 7.11 Novartis Sales, 2013 –Split by Business Segments (USD Million, %)
Figure 7.12 bioMérieux Sales, 2013 –Split by Business Segments (USD Million, %)
Figure 8.1 Stakeholders in the Theranostics Market
Figure 8.2 Business Models for Companion Diagnostic Development
Figure 9.1 Efficacy Rate of Drugs (%)
Figure 9.2 Reasons for Drug Failure in Phase II of Clinical Trials, 2008-2010
Figure 9.3 Reasons for Drug Failure in Phase III of Clinical Trials, 2007-2010
Figure 9.4 Pipeline Drugs Attached with Biomarkers - by Phase of Development (%)
Figure 9.5 Cost of Genome Sequencing (USD) - per Mega base, 2001-2012

List of Tables

Table 4.1 Companion Drugs Approved by FDA
Table 4.2 Companion Drugs Approved by the EMA
Table 5.1 List of Marketed Companion Diagnostic Tests, 2014
Table 5.2 List of Companion Diagnostics in Pipeline
Table 6.1 Proposed Classification of IVDs
Table 6.2 List of Companion Diagnostics Tests Conducted in France, 2013
Table 6.3 NICE Technology Appraisals of Drugs with Companion Diagnostics
Table 6.4 Japan’s Population Over 65 - 2010, 2015 and 2020 (’000, %)
Table 7.1 Abbott Molecular: Marketed Companion Diagnostic Tests
Table 7.2 Abbott Molecular: Pipeline Companion Diagnostic Tests
Table 7.4 Qiagen: Pipeline Companion Diagnostic Tests
Table 7.5 Dako: Marketed Companion Diagnostic Tests
Table 7.6 Roche: Marketed Companion Diagnostic Tests
Table 7.7 Novartis: Marketed Companion Drugs
Table 7.8 Novartis: Pipeline Companion Diagnostic Tests
Table 8.1 Deals and Collaborations for Companion Diagnostic Development, January 2011 - Present
Table 8.2 Companies providing Ancillary Services
Table 9.1 Drug Recalls from the US Market, 1996-2007
Table 9.2 SWOT Analysis of Companion Diagnostics Market
Table 12.1 List of New Molecular Entities (NMEs) Approved with Pharmacogenomic Biomarker
Table 12.2 Companion Drugs Market, 2013 - by Leading Drugs (USD million)
Table 12.3 Companion Drugs Market, 2013 - by Leading Indication (USD million, %)
Table 12.4 Companion Drugs Market, 2013- by Leading Companies (USD million, %)
Table 12.5 Herceptin Sales, 1998 - 2013 (USD million)
Table 12.6 Xalkori Sales, 2011- 2013 (USD Million)
Table 12.7 Zelboraf Sales, 2011 - 2013 (USD Million)
Table 12.8 Iressa Sales, 2005 - 2013 (USD million)
Table 12.9 Kalydeco Sales, 2012- 2013 (USD Million)
Table 12.10 Global Companion Diagnostics Market, Number of Tests: Split by Category, 2014 - 2024 (# ‘000)
Table 12.11 Global Companion Diagnostics Market, Sales Forecast: Split by Category, 2014 - 2024 (USD MM)
Table 12.12 US Companion Diagnostics Market, Number of Tests: Split by Category, 2014 - 2024 (# ‘000)
Table 12.13 US Companion Diagnostics Market, Sales Forecast: Split by Category, 2014 - 2024 (USD MM)
Table 12.14 EU5 Companion Diagnostics Market, Number of Tests: Split by Category, 2014 - 2024 (# ‘000)
Table 12.15 EU5 Companion Diagnostics Market, Sales Forecast: Split by Category, 2014 - 2024 (USD MM)
Table 12.16 Global KRAS Market, Number of Tests, 2014 - 2024 (# ‘000)
Table 12.17 Global KRAS Market, Sales Forecast, 2014 - 2024 (USD MM)
Table 12.18 Global EGFR Market, Number of Tests: Split by Indication, 2014 - 2024 (# ‘000)
Table 12.19 Global EGFR Market, Sales Forecast: Split by Indication, 2014 - 2024 (USD MM)
Table 12.20 Global HER2 Market, Number of Tests: Split by Indication, 2014 - 2024 (# ‘000)
Table 12.21 Global HER2 Market, Sales Forecast: Split by Indication, 2014 - 2024 (USD MM)
Table 12.22 Global ALK Market, Number of Tests, 2014 - 2024 (# ‘000)
Table 12.23 Global ALK Market, Sales Forecast, 2014 - 2024 (USD MM)
Table 12.24 Other Companion Diagnostics, Global Number of Tests, 2014 - 2024 (# ‘000)
Table 12.25 Other Companion Diagnostics, Global Sales Forecast, 2014 - 2024 (USD MM)
Table 12.26 Global Metastatic NSCLC Companion Diagnostic Tests, 2014 - 2024 (# '000)
Table 12.27 Global Metastatic NSCLC Companion Diagnostic Test Sales Forecast, 2014 - 2024 (USD MM)
Table 12.28 Global Metastatic Colorectal Cancer Companion Diagnostic Tests, 2014 - 2024 (# '000)
Table 12.29 Global Metastatic Colorectal Cancer Companion Diagnostic Test Sales Forecast, 2014 - 2024 (USD MM)
Table 12.30 Global Breast Cancer Companion Diagnostic Tests, 2014 - 2024 (# '000)
Table 12.31 Global Breast Cancer Companion Diagnostic Test Sales Forecast, 2014 - 2024 (USD MM)
Table 12.32 Global Melanoma Companion Diagnostic Tests, 2014 - 2024 (# '000)
Table 12.33 Global Melanoma Companion Diagnostic Test Sales Forecast, 2014 - 2024 (USD MM)
Table 12.34 US Marketed and Pipeline Companion Diagnostics, Number of Tests: Split by Type of Test, 2014 - 2024 (# '000)
Table 12.35 US Marketed and Pipeline Companion Diagnostics, Sales Forecast: Split by Type of Test, 2014 - 2024 (USD MM)
Table 12.36 US KRAS Market, Number of Tests, 2014 - 2024 (# '000)
Table 12.37 US KRAS Market, Sales Forecast, 2014 - 2024 (USD MM)
Table 12.38 US EGFR Market, Number of Tests: Split by Indication, 2014 - 2024 (# '000)
Table 12.39 US EGFR Market, Sales Forecast: Split by Indication, 2014 - 2024 (USD MM)
Table 12.40 US HER2 Market, Number of Tests: Split by Indication, 2014 - 2024 (# '000)
Table 12.41 US HER2 Market, Sales Forecast: Split by Indication, 2014 - 2024 (USD MM)
Table 12.42 US ALK Market, Number of Tests: Split by Indication, 2014 - 2024 (# '000)
Table 12.43 US ALK Market, Sales Forecast: Split by Indication, 2014 - 2024 (USD MM)
Table 12.44 Other Companion Diagnostics in the US, Number of Tests, 2014 - 2024 (# '000)
Table 12.45 Other Companion Diagnostics in the US, Sales Forecast, 2014 - 2024 (USD MM)
Table 12.46 US NSCLC Companion Diagnostic Tests, 2014 - 2024 (# '000)
Table 12.47 US NSCLC Companion Diagnostic Test Sales Forecast, 2014 - 2024 (USD MM)
Table 12.48 US Metastatic Colorectal Cancer Companion Diagnostic Tests, 2014 - 2024 (# '000)
Table 12.49 US Metastatic Colorectal Cancer Companion Diagnostic Test Sales Forecast, 2014 - 2024 (USD MM)
Table 12.50 US Breast Cancer Companion Diagnostic Tests, 2014 - 2024 (# '000)
Table 12.51 US Breast Cancer Companion Diagnostic Test Sales Forecast, 2014 - 2024 (USD MM)
Table 12.52 US Melanoma Companion Diagnostic Tests, 2014 - 2024 (# '000)
Table 12.53 US Melanoma Companion Diagnostic Test Sales Forecast, 2014 - 2024 (USD MM)
Table 12.54 Number of KRAS Tests Performed in France, 2007-2012
Table 12.55 Number of EGFR Tests Performed in France, 2008-2011
Table 12.56 Number of HER2, KRAS, EGFR and KIT Tests Performed in England, 2010 - 2011
Table 12.57 EU5 Marketed and Pipeline Companion Diagnostics, Number of Tests: Split by Type of Test, 2014 - 2024 (# '000)
Table 12.58 EU5 Marketed and Pipeline Companion Diagnostics, Sales Forecast: Split by Type of Test, 2014 - 2024 (USD MM)
Table 12.59 EU5 KRAS Market, Number of Tests, 2014 - 2024 (# '000)
Table 12.60 EU5 KRAS Market, Sales Forecast, 2014 - 2024 (USD MM)
Table 12.61 EU5 EGFR Market, Number of Tests: Split by Indication, 2014 - 2024 (# '000)
Table 12.62 EU5 EGFR Market, Sales Forecast: Split by Indication, 2014 - 2024 (USD MM)
Table 12.63 EU5 HER2 Market, Number of Tests: Split by Indication, 2014 - 2024 (# '000)
Table 12.64 EU5 HER2 Market, Sales Forecast: Split by Indication, 2014 - 2024 (USD MM)
Table 12.65 EU5 ALK Market, Number of Tests: Split by Indication, 2014 - 2024 (# '000)
Table 12.66 Other Companion Diagnostics in EU5, Number of Tests, 2014 - 2024 (# '000)
Table 12.67 Other Companion Diagnostics in EU5, Sales Forecast, 2014 - 2024 (USD MM)
Table 12.68 EU5 Metastatic NSCLC Companion Diagnostic Tests, 2014 - 2024 (# '000)
Table 12.69 EU5 Metastatic NSCLC Companion Diagnostic Test Sales Forecast, 2014 - 2024 (USD MM)
Table 12.71 EU5 Metastatic Colorectal Cancer Companion Diagnostic Tests, 2014 - 2024 (# '000)
Table 12.72 EU5 Metastatic Colorectal Cancer Companion Diagnostic Test Sales Forecast, 2014 - 2024 (USD MM)
Table 12.73 EU5 Breast Cancer Companion Diagnostic Tests, 2014 - 2024 (# '000)
Table 12.74 EU5 Breast Cancer Companion Diagnostic Test Sales Forecast, 2014 - 2024 (USD MM)
Table 12.75 EU5 Melanoma Companion Diagnostic Tests, 2014 - 2024 (# '000)
Table 12.76 EU5 Melanoma Companion Diagnostic Test Sales Forecast, 2014 - 2024 (USD MM)
Table 12.77 Abbott Laboratories Sales, 2013 - by Business Segments (USD million, %)
Table 12.78 Abbott Laboratories Sales, 2013 – Diagnostics Segments (USD million, %)
Table 12.79 Qiagen Sales, 2013 - by Business Segments (USD million, %)
Table 12.80 Qiagen Personalized Healthcare Sales, 2012 (USD million, %)
Table 12.81 Agilent Technologies Sales, 2013 - by Business Segments (USD million, %)
Table 12.82 Roche Group Sales, 2013 - by Business Segments (USD million, %)
Table 12.83 Roche Diagnostics Sales, 2013 - by Segments (USD million, %)
Table 12.84 Novartis Sales, 2013 - by Business Segments (USD million, %)
Table 12.85 bioMérieux Sales, 2013 - by Business Segments (USD million, %)
Table 12.86 Cost of Genome Sequencing (USD) - per Megabase, 2001-2012

Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Companion Diagnostics Market (2nd Edition), 2014 – 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>Web Address</td>
<td><a href="http://www.researchandmarkets.com/reports/2867314/">http://www.researchandmarkets.com/reports/2867314/</a></td>
</tr>
<tr>
<td>Office Code</td>
<td>SC</td>
</tr>
</tbody>
</table>

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF)</td>
<td>Single User</td>
<td>USD 1899</td>
</tr>
<tr>
<td>Electronic (PDF)</td>
<td>Site License</td>
<td>USD 3999</td>
</tr>
<tr>
<td>Electronic (PDF)</td>
<td>Enterprisewide</td>
<td>USD 6499</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Title</th>
<th>Mr</th>
<th>Mrs</th>
<th>Dr</th>
<th>Miss</th>
<th>Ms</th>
<th>Prof</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Last Name:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Email Address: *</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Job Title:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phone Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by Wire Transfer: Bank details will be provided on the invoice which you will receive after you place your order with us.

If you have a Marketing Code please enter it below:

Marketing Code: _____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World